Hydroxychloroquine is, for most people who take it, protective of the kidneys rather than harmful to them. The drug is a cornerstone of lupus treatment precisely because it slows kidney function decline in lupus nephritis, and large studies consistently support that benefit. But the picture has a few genuine wrinkles: rare cases of a specific kidney cell injury called phospholipidosis have been documented, animal research suggests HCQ may worsen certain forms of acute kidney injury, and existing kidney disease changes how the drug is cleared from the body in ways that matter for other side effects. The honest answer is that HCQ rarely damages healthy kidneys directly, yet the relationship between the drug and kidney health is more layered than a simple yes or no.
The Kidney-Protective Effect in Lupus
The strongest body of evidence on HCQ and the kidneys comes from lupus nephritis, a condition in which the immune system attacks the kidneys. Here, hydroxychloroquine consistently looks like a friend to the kidneys, not a threat. A study tracking lupus nephritis patients over years found that those who took HCQ had roughly a 60% lower risk of losing significant kidney filtration capacity compared to those who did not take it. Among patients who already had moderate-to-severe kidney disease, the protective effect was even larger, with about a 77% lower risk of further decline.1PubMed Central. Hydroxychloroquine Associated With Lower Glomerular Filtration Rate Decline in Lupus Nephritis – Section: RESULTS In practical terms, HCQ slowed the annual loss of kidney function by roughly 3 to 5 units of filtration rate within the first decade of diagnosis.
Separate research looked at whether HCQ could help patients whose kidneys had already taken a hit. In patients with lupus nephritis and reduced kidney function, those on hydroxychloroquine were nearly four times more likely to recover kidney function than those who were not taking it. Patients who recovered kidney function within six months also had a lower chance of progressing to end-stage kidney disease, where dialysis or transplant becomes necessary.2PubMed. Recovery of renal function in patients with lupus nephritis and reduced renal function: the beneficial effect of hydroxychloroquine – Section: RESULTS
These findings are why rheumatologists recommend hydroxychloroquine as lifelong therapy for virtually all lupus patients, not in spite of kidney concerns but partly because the drug protects the kidneys from the disease itself. The immunomodulatory and anti-inflammatory effects of HCQ appear to dampen the autoimmune assault on kidney tissue, reducing the scarring and filtration loss that lupus nephritis causes over time.
Phospholipidosis, the Rare Direct Kidney Injury
There is, however, a documented way hydroxychloroquine can directly harm kidney cells. HCQ belongs to a family of drugs that accumulate inside cellular compartments called lysosomes. Over long periods of use, this accumulation can overwhelm the cell’s ability to break down certain fats, causing them to pile up in characteristic layered structures. When this happens in kidney cells, the condition is called renal phospholipidosis.
In reported cases, kidney biopsies from patients on long-term HCQ have revealed structures known as myeloid or lamellar bodies inside podocytes, the specialized cells that form the kidney’s filtration barrier.3PubMed Central. Hydroxychloroquine-Induced Renal Phospholipidosis – Section: Abstract Under an electron microscope, these structures sometimes appear as so-called “zebra bodies,” concentric rings of membrane material stacked inside the cells. Zebra bodies have been found in podocytes, mesangial cells, endothelial cells, and parietal epithelial cells of patients taking HCQ.4PubMed Central. Lupus Nephritis and Hydroxychloroquine-Associated Zebra Bodies: Not Just in Fabry Disease – Section: Results
These findings can create a diagnostic headache. Zebra bodies are the hallmark of Fabry disease, a genetic condition where a missing enzyme causes fat buildup in cells throughout the body. A pathologist reading a kidney biopsy from a lupus patient on HCQ might see these structures and initially suspect Fabry disease. However, the zebra bodies caused by HCQ tend to be much smaller and less abundant than those seen in Fabry disease.4PubMed Central. Lupus Nephritis and Hydroxychloroquine-Associated Zebra Bodies: Not Just in Fabry Disease – Section: Results Similar curvilinear bodies have been confirmed in separate biopsy reports from HCQ patients, with the multilamellar structures appearing predominantly in the glomerular visceral epithelial cells and to a lesser degree in other cell types.5Clinical Kidney Journal. Curvilinear bodies in hydroxychloroquine-induced renal phospholipidosis resembling Fabry disease – Section: Kidney biopsy
The clinical significance of HCQ-induced phospholipidosis in the kidney is still debated. In most reported cases, the patients already had lupus nephritis, making it difficult to separate the drug’s effects from the disease’s effects. The fat-laden structures are clearly present on biopsy, but whether they impair kidney function on their own or simply represent a microscopic curiosity remains an open question. Published cases remain rare enough that this is not a routine concern for the average patient on standard doses.
When HCQ May Worsen Acute Kidney Injury
A more unsettling finding comes from animal research. A study using a mouse model of lupus nephritis found that giving hydroxychloroquine before an episode of acute kidney injury actually made the injury worse, not better. Mice that received HCQ before the kidney insult showed more damage to the tubular cells that line the kidney’s drainage system, with increased cell death and higher levels of a tubular injury marker. Recovery from the acute injury was also delayed in HCQ-treated mice.6PubMed Central. Hydroxychloroquine administration exacerbates acute kidney injury complicated by lupus nephritis – Section: Results
The mechanism appears to involve HCQ’s effects on the cell cycle and on autophagy, a cleanup process cells use to recycle damaged parts. HCQ blocked tubular cells from dividing to replace injured ones, essentially stalling the repair process. It also disrupted the autophagy-lysosomal pathway, which accelerated cellular aging in the damaged tubular cells.6PubMed Central. Hydroxychloroquine administration exacerbates acute kidney injury complicated by lupus nephritis – Section: Results
This is important context, but it comes with caveats. It is a mouse study, not a human trial. Acute kidney injury in mice does not perfectly replicate the complex clinical situations in which human lupus patients experience sudden kidney function drops. Human studies, as described earlier, consistently show that HCQ use correlates with better long-term kidney outcomes in lupus. Still, the finding raises a reasonable question about whether HCQ might behave differently in the context of an acute kidney event versus chronic autoimmune kidney disease, and it is one reason clinicians pay attention to kidney function in patients on the drug.
How Existing Kidney Disease Changes HCQ in the Body
Even if HCQ does not commonly damage kidneys directly, existing kidney disease changes how the drug moves through your body in ways that matter. The kidneys are the primary route through which hydroxychloroquine is cleared from the bloodstream. When kidney function drops, less of the drug is eliminated, and blood levels rise. A pharmacokinetic modeling study predicted that patients with chronic kidney disease would have altered drug exposure compared to healthy individuals, which has practical implications for dosing.7Europe PMC / Pharmaceutics. Predicting Hydroxychloroquine Clearance in Healthy and Diseased Populations Using a Physiologically Based Pharmacokinetic Approach
This reduced clearance matters most for one particular side effect: retinal toxicity. HCQ can damage the retina over years of use, and one of the strongest risk factors for this complication is impaired kidney function. A landmark study found that a 50% drop in kidney filtration roughly doubled the risk of hydroxychloroquine retinopathy, because the kidneys’ inability to clear the drug effectively exposes the retina to higher cumulative doses.8JAMA Ophthalmology. The Risk of Toxic Retinopathy in Patients on Long-term Hydroxychloroquine Therapy – Section: Results A more recent study confirmed that chronic kidney disease at stage 3 or greater is an independent risk factor for developing hydroxychloroquine retinopathy, likely because of this higher effective drug exposure.9PubMed Central. Risk Factors for Hydroxychloroquine Retinopathy and Its Subtypes – Section: Discussion
So the kidney-HCQ relationship runs in both directions. The drug generally protects the kidneys in autoimmune disease, but damaged kidneys make the drug accumulate and increase the risk of harm elsewhere, particularly to the eyes.
Dose Adjustments When Kidneys Are Impaired
Because of reduced clearance, guidelines have recommended cutting the HCQ dose by half for patients whose kidney filtration rate drops below about 30% of normal. The evidence base behind this specific recommendation is not strong by clinical-trial standards. It is based more on pharmacological reasoning (less clearance means higher levels, so give less drug) than on randomized trials proving a particular dose is safer. As one group of rheumatologists acknowledged, the recommendation for dose reduction in severe CKD is not supported by high-level evidence, but given what we know about how the drug is eliminated, it is a reasonable precaution.10Annals of the Rheumatic Diseases. Hydroxychloroquine in systemic lupus erythematosus and chronic kidney disease
The tension here is real. HCQ is recommended as lifelong therapy for lupus because the benefits for disease control and kidney protection are so well established. But the longer someone takes it, the higher the cumulative dose, and the greater the risk of retinal toxicity. For patients who also have reduced kidney function, that cumulative exposure is amplified. Clinicians try to thread the needle: keep the dose high enough to control the autoimmune disease and protect the kidneys, but low enough to minimize the retinal risk that kidney impairment magnifies. With newer screening techniques, retinal toxicity from HCQ is being detected more frequently than in past decades, reaching about 10 to 20% of patients after 20 or more years of use.10Annals of the Rheumatic Diseases. Hydroxychloroquine in systemic lupus erythematosus and chronic kidney disease That statistic underscores why regular eye exams are non-negotiable for anyone on long-term hydroxychloroquine, especially if kidney function is compromised.
What Patients Actually Worry About
Patient surveys reveal that kidney damage is a common concern among people prescribed hydroxychloroquine. In qualitative interviews about medication adherence, patients described worrying about dark urine as a possible sign that HCQ was affecting their kidneys, and anxiety about what regular urine tests might reveal about organ damage from the drug.11PubMed Central. Patient and healthcare team recommended medication adherence strategies for hydroxychloroquine: results of a qualitative study informing intervention development – Section: Results These worries can drive people to skip doses or stop the drug entirely, which for lupus patients is one of the most dangerous things they can do. Stopping HCQ is associated with disease flares that can cause the very kidney damage patients are trying to avoid.
The irony is that the vast majority of evidence points the other direction. For lupus patients, the risk of kidney damage from stopping HCQ is far greater than the risk of kidney damage from taking it. Changes in urine color on HCQ are typically benign and related to the drug’s metabolism rather than kidney injury. If you are on hydroxychloroquine and notice changes in your urine, the appropriate step is to mention it at your next visit rather than to stop taking the medication.
Clinicians and patients sometimes talk past each other on this point. The doctor knows HCQ is kidney-protective. The patient reads the drug label, sees “renal” in the side-effect warnings, and understandably worries. Better communication about the specific ways HCQ interacts with kidney function, as opposed to vague warnings that can be misread, could help patients stay on a drug that overwhelmingly works in their favor.
Distinguishing Drug Effect From Disease Effect
One of the trickiest aspects of evaluating HCQ’s kidney impact is that the people who take the drug most often already have a disease that attacks the kidneys. Lupus nephritis, by its nature, causes protein in the urine, declining filtration rates, and sometimes kidney failure. When a patient on HCQ develops worsening kidney function, the natural question is whether the drug or the disease is responsible. In most cases, the answer is the disease. Lupus nephritis flares, incomplete treatment responses, and progression of scarring in the kidneys are far more common causes of declining function than any direct HCQ toxicity.
The phospholipidosis findings on biopsy, discussed earlier, illustrate this difficulty. The zebra bodies and lamellar structures found in podocytes are a drug effect, but they show up in patients whose kidneys are already under immune attack. Whether those microscopic changes translate into meaningful functional decline above and beyond what the disease itself causes is uncertain. In practice, pathologists note the findings, clinicians factor them into their overall assessment, and treatment decisions usually still favor continuing HCQ because the alternative, uncontrolled lupus nephritis, is far more dangerous to the kidneys.
Pregnancy and Kidney Considerations
Hydroxychloroquine is one of the few autoimmune medications considered safe during pregnancy, which matters for kidney health because lupus flares during pregnancy can be devastating to both maternal kidneys and fetal outcomes. A study examining children born to mothers with lupus who took HCQ during pregnancy found no significant negative outcomes in the exposed children.12PubMed Central. Outcomes of children born to mothers with systemic lupus erythematosus exposed to hydroxychloroquine or azathioprine – Section: Results Continuing HCQ through pregnancy is generally recommended for lupus patients precisely because stopping it raises the risk of a flare that could precipitate lupus nephritis or worsen existing kidney involvement at one of the most vulnerable times.
For pregnant patients who already have impaired kidney function from lupus nephritis, the calculus is the same as in non-pregnant patients, but the stakes feel higher. The drug stays because the disease, unchecked, is worse. Dose adjustments may be considered if kidney function is significantly reduced, but the core principle holds: the kidney risk comes from stopping HCQ, not from continuing it.
Beyond Lupus
Hydroxychloroquine is prescribed for conditions other than lupus, including rheumatoid arthritis, Sjögren syndrome, and occasionally off-label uses. In rheumatoid arthritis patients, kidney problems from HCQ are essentially unreported as a clinical concern. The phospholipidosis cases in the literature are overwhelmingly in lupus patients who have been on the drug for years at relatively high cumulative doses, often alongside other medications that also affect the kidneys. There is no evidence that standard-dose HCQ for rheumatoid arthritis poses a meaningful kidney risk.
The brief, intense public interest in hydroxychloroquine during the early COVID-19 pandemic brought kidney questions into the spotlight for a different population: people without autoimmune disease who might take the drug short-term. Short courses of HCQ at standard doses have not been linked to kidney injury in people with normal kidney function. The kidney considerations that matter clinically are specific to long-term use in patients who often already have kidney involvement from their underlying disease.
If you are taking hydroxychloroquine for any condition, the most productive monitoring steps are periodic blood tests for kidney function, regular eye exams for retinal screening (especially after five years of use or sooner if you have kidney disease), and honest conversations with your prescriber about any symptoms that concern you. The drug’s track record for kidney safety is reassuring for the overwhelming majority of patients, and the conditions it treats pose a far greater kidney threat than the medication itself.